Esomeprazole

Limits on what this shows

• Key negative/null findings: Esomeprazole alone had minimal cytotoxic effect on SNU-1 cells [20]. LOTUS/SOPRAN reported no major safety concerns over 5 to 12 years [2], though no mitochondrial marker was measured.
• At-risk subgroups: None established.

Regulatory status

Not addressed in the Nexium label sections retrieved [1].

Population evidence

Tier B only. Marino et al. 2010 [19]: esomeprazole 160 micromolar in Me30966, Mel501 and WM793 melanoma lines produced mitochondrial membrane depolarization, cytochrome c release and ROS; N-acetylcysteine blocked ROS and cell death. Joha et al. 2025 [20]: SNU-1 gastric carcinoma cells; esomeprazole alone minimal effect, but with cisplatin there was more oxidative stress, mitochondrial dysfunction and DNA damage than cisplatin alone.

Mechanism

Named, in vitro: mitochondrial membrane depolarization in acidic, tumor-cell contexts. Whether therapeutic plasma concentrations reach comparable effects in normal tissue is not shown in the sources opened.

Counter-evidence held on record

Both studies used cancer cell lines and drug concentrations not benchmarked to human exposure; the second is a cisplatin-combination study in which esomeprazole alone was close to inactive. Not a finding of mitochondrial damage in patients and not a CoQ10 or other mitochondrial-nutrient deficiency. No supplementation is recommended.

Limits on what this shows

• Key negative/null findings: Joha et al. 2025 [20]: esomeprazole alone had minimal effect on gastric carcinoma cells; oxidative stress rose only in combination with cisplatin. Koch [16]: no colonic antioxidant change.
• At-risk subgroups: None established.

Regulatory status

Not addressed in the Nexium label sections retrieved [1].

Population evidence

No human data. Tier B: Abed et al. 2020 [17], DPPH radical-scavenging assay against ascorbic acid; omeprazole and esomeprazole scavenged most, IC50 18.7 +/- 5.7 micromolar (omeprazole) and 5.7 micromolar (esomeprazole), rabeprazole least. Koch et al. 2004 [16], A/J mice, n=10 per group, esomeprazole magnesium by gavage for 10 days: at 50 mg/kg/day gastric total antioxidant capacity rose about 50% (dose-dependent, p<0.001) and Cu/Zn-superoxide dismutase activity rose (p=0.03) in stomach, no significant colonic change. Xie et al. 2019 [18], rat stress-ulcer model: esomeprazole pretreatment enhanced antioxidant defenses and reduced NF-kB/MAPK inflammatory signaling. Opposite direction: Marino et al. 2010 [19], three human melanoma lines at 160 micromolar esomeprazole: rapid hydrogen peroxide and superoxide accumulation via mitochondrial dysfunction and NADPH oxidase, blocked by N-acetylcysteine. Class: Lee 2022 [21] PPIs (agents not itemized in the abstract) inhibited V-ATPase and were reported to induce lysosomal and ER stress with ROS accumulation and increased SOD activity.

Mechanism

Named in both directions: direct radical scavenging by the benzimidazole structure (chemistry [17]); induction of protective enzyme systems in gastric tissue [16][18]; pro-oxidant mitochondrial and NADPH-oxidase activation in tumor cells at high concentration [19]. Concentrations were not benchmarked against human plasma exposure in the sources opened.

Counter-evidence held on record

The directions conflict by model: protective in chemistry and healthy rodent tissue, pro-oxidant in cancer cells at 160 micromolar, so no net direction can be asserted for patients. No antioxidant-capacity or redox biomarker was measured in any esomeprazole-treated human in the sources opened. This is a mechanism-level finding, not an antioxidant deficiency, and the reverse-direction signal is not evidence that esomeprazole is protective. It does not support antioxidant supplementation; no recommendation is made.

Limits on what this shows

• Key negative/null findings: LOTUS/SOPRAN routine hematology showed no clinically relevant change over 5 to 12 years [2]. Ferritin did not differ significantly among PPIs [4].
• At-risk subgroups: Not established for esomeprazole. Duration and dose gradient reported for the class [9].

Regulatory status

Nexium label [1] section 7: esomeprazole can reduce the absorption of other drugs because of reduced intragastric acidity; the passage retrieved does not name iron, so iron is not confirmed as a label-listed interaction. The label contains no mention of iron deficiency as a warning.

Population evidence

Tier C: Lam et al. 2017 [9], Gastroenterology, 77,046 patients with new iron deficiency versus 389,314 controls; 2 or more years of PPI use aOR 2.49 (95% CI 2.35 to 2.64), H2 blockers aOR 1.58 (1.46 to 1.71); risk rose with dose and duration and fell after discontinuation. Agent breakdown and esomeprazole's inclusion were not available in the abstract opened. Esomeprazole in cohort: Nafea et al. 2026 [4], ferritin below 30 ng/mL in 29 of 61 esomeprazole users (47.5%) versus 32.7% omeprazole, p=0.089 (not significant), no non-PPI control. Tier B, omeprazole stand-in (racemic parent of esomeprazole, labeled as such): Hamano et al. [10] report omeprazole raised hepcidin via the aryl hydrocarbon receptor and lowered duodenal ferroportin in HepG2 cells and mice, with FAERS signals; esomeprazole was not highlighted as a test agent in the text opened.

Mechanism

Two named routes, both class-level for esomeprazole: reduced acid-dependent solubilization of non-heme iron, and hepcidin-mediated ferroportin suppression (omeprazole, [10]). Neither has been demonstrated for esomeprazole in a controlled study.

Counter-evidence held on record

Competing explanation: PPIs are prescribed for GI bleeding, NSAID gastropathy and ulcer disease, all of which cause iron loss, so confounding by indication is presumed (Hard Rule 6). The reduction of risk after stopping [9] argues partly against pure indication effect but does not exclude it. Iron deficiency here is a class association, not an esomeprazole-measured effect. Iron supplementation is not recommended by this dossier, and iron overload is a risk of unneeded supplementation; no dose is given.

Limits on what this shows

• Key negative/null findings: None located for esomeprazole. A consumer page [25] says long-term PPI use "has been associated with modestly lower mean serum copper" while conceding most values stay within range and that omeprazole labeling does not list copper.
• At-risk subgroups: None established.

Regulatory status

The Nexium label sections retrieved [1] contain no mention of copper.

Population evidence

Matsui et al. 2015 [11], J Invest Dermatol, Tier B in vitro/ex vivo: omeprazole (lead compound) inhibited relocalization of ATP7A from the trans-Golgi network to the plasma membrane in response to elevated copper in B16F10 melanoma cells, human melanocytes, reconstructed skin and Menkes fibroblasts; related PPIs including esomeprazole were reported to show similar activity with differing toxicity. The effect needed 48 to 72 hours, was not fully reversed by copper, and increased cellular sensitivity to copper toxicity. No human serum copper, ceruloplasmin or copper-deficiency study with esomeprazole in the cohort was opened. The PPI-copper deficiency myelopathy case-report lead and a CBC/trace-element pilot study could not be opened (ResearchGate 429) and are not relied on.

Mechanism

Named but cellular: ATP7A trafficking blockade. Its direction is toward copper retention and sensitivity inside cells, not toward systemic loss, so it does not by itself predict low serum copper.

Counter-evidence held on record

Matsui's experiments were designed around melanogenesis, used omeprazole as the main agent, and do not measure circulating copper. The consumer claim of lower serum copper is listed under Fails verification. Copper is an independent entry and is not merged with Iron. The cellular finding is not a copper deficiency; copper supplementation is not recommended and could be harmful; no dose is given.

Limits on what this shows

• Key negative/null findings: A 12-infant pre-post esomeprazole study (Castellani et al.) reported no significant microbiome changes; this is known only through a critical commentary [15], which argues the study was underpowered and lacked an untreated control. The meta-analysis [14] notes mixed designs, one infant study and no individual-level confounder adjustment.
• At-risk subgroups: Not established for esomeprazole; hospitalized patients are named in the label for C. difficile [1].

Regulatory status

Nexium label [1] section 5.3 warns that PPI therapy may be associated with an increased risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients, and advises the lowest dose and shortest duration. That is a clinical infection outcome from observational data, not a microbiome measurement, and is not graded as a nutrient finding.

Population evidence

Mishiro et al. 2017 [12] (Tier A, esomeprazole in cohort): 10 healthy adults given esomeprazole 20 mg daily for 4 weeks; 16S rRNA sequencing of fecal, salivary and periodontal samples; significant differences in species richness across sample types, a higher ratio of Streptococcus in feces and decreases in other genera including Neisseria and Veillonella (as summarised in the abstract; the per-sample-type split was not resolved). Class-level support, Tier C because esomeprazole's presence in the cohorts could not be confirmed from the text opened: Imhann et al. [13], 1,815 participants in three cohorts, 211 current PPI users, lower Shannon diversity, about 20% of taxa altered, oral-type bacteria (Rothia) and Enterococcus, Streptococcus, Staphylococcus and Escherichia coli increased; Zhang et al. 2023 [14], meta-analysis of 4 studies and 292 stool samples, lower Shannon index and depletion of Ruminococcaceae and Lachnospiraceae (short-chain fatty acid producers).

Mechanism

Named: reduced gastric acid removes a barrier to survival of swallowed oral and environmental bacteria, which is the interpretation the PPI literature offers [13]. This is a consequence of the intended pharmacology and is graded here as a microbiome-composition effect, not as acid suppression itself.

Customer-visible string

In a small 4-week study of healthy adults, esomeprazole shifted the makeup of gut and mouth bacteria. Whether this matters for health in long-term users has not been shown.

Counter-evidence held on record

The only esomeprazole-specific interventional study is small (n=10), healthy volunteers, no parallel control; the infant esomeprazole study is reported null [15]. Observational cohorts [13] are confounded by indication, age and co-medication. A change in microbial composition is not a nutrient deficiency and is not evidence of disease. It does not support probiotic or supplement use, and no recommendation is made.

Limits on what this shows

• Key negative/null findings: LOTUS/SOPRAN hematology null [2].
• At-risk subgroups: Not established.

Regulatory status

Nexium label [1]: anemia appears among clinical-trial adverse reactions (section 6.1); frequencies were not retrieved. Postmarketing hematologic reactions listed are agranulocytosis and pancytopenia, which are not oxygen-delivery findings.

Population evidence

Hematology was a routine laboratory variable in LOTUS (esomeprazole) and SOPRAN (omeprazole): no clinically relevant change over 5 to 12 years [2]. The only route to reduced oxygen-carrying capacity is the iron pathway (Tier C, [9]; Tier B omeprazole, [10]); see the Iron entry. No study opened measured hemoglobin trajectories, red-cell mass, arterial oxygenation or tissue oxygen delivery in esomeprazole users.

Mechanism

Indirect only, via any iron deficiency (Iron entry). No direct mechanism on oxygen transport or utilization is identified.

Counter-evidence held on record

Anemia is a clinical outcome with many causes (GI blood loss from the treated condition, chronic disease); it is not iron deficiency and not an oxygen-delivery deficiency (Hard Rule 2). This entry is a context flag and shares its evidence with the Iron entry (Overlap map). Do not read this as esomeprazole impairing oxygen delivery. It records that the label lists anemia and that the evidence base for a mechanism is the iron class literature. No recommendation to supplement is made.

Limits on what this shows

• Key negative/null findings: None retrievable.
• At-risk subgroups: None established.

Regulatory status

Not addressed in the Nexium label sections retrieved [1].

Population evidence

No human data. Indirect Tier B: Marino et al. 2010 [19] (mitochondrial depolarization; ATP not reported in the text opened). Identified but unread: Pastoris et al. 2008 [22], Naunyn-Schmiedeberg's Arch Pharmacol, whose title states effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in rat gastric mucosa treated with indomethacin; only bibliographic metadata could be retrieved (Springer 429, PubMed CAPTCHA), so no result or direction is claimed. This is why the entry is graded yellow rather than ungraded: a Tier B esomeprazole study that measured the category exists, but its findings are inaccessible and flagged for re-check.

Mechanism

Named but untested: mitochondrial depolarization could in principle reduce ATP synthesis. The drug's intended target, the gastric H+/K+-ATPase, consumes ATP and is not ATP production; that intended pharmacology is not graded (Hard Rule 2).

Counter-evidence held on record

Because the only ATP-relevant study is unread, the direction (protective or impairing) is unknown. Fatigue or "low energy" attributed to PPIs in consumer material is usually routed through B12 or magnesium, which are graded separately. ATP production is its own entry and is not merged with Mitochondrial burden or Oxygen delivery/utilization. This is a placeholder for re-check, not evidence that esomeprazole affects cellular energy. No supplementation is recommended.